−1.62USD
−69.13 MUSD
23.31 M
About Tyra Biosciences, Inc.
Sector
Industry
CEO
Todd J. Harris
Website
Headquarters
Carlsbad
Employees (FY)
49
Founded
2018
ISIN
US90240B1061
FIGI
BBG00RCQD9D1
Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Its proprietary in-house discovery platform, SNÅP, enables the rapid and precise refinement of structural design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA is developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR) family members, which are altered in approximately 7% of all cancers. The company was founded by Daniel Bensen and Todd Harris on August 2, 2018 and is headquartered in Carlsbad, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of TYRA is 14.66 USD — it has increased by 1.45% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Tyra Biosciences, Inc. stocks are traded under the ticker TYRA.
Tyra Biosciences, Inc. is going to release the next earnings report on May 2, 2024. Keep track of upcoming events with our Earnings Calendar.
TYRA stock is 4.43% volatile and has beta coefficient of 2.79. Check out the list of the most volatile stocks — is Tyra Biosciences, Inc. there?
One year price forecast for Tyra Biosciences, Inc. has a max estimate of 28.00 USD and a min estimate of 22.00 USD.
TYRA earnings for the last quarter are −0.49 USD whereas the estimation was −0.35 USD which accounts for −38.68% surprise. Estimated earnings for the next quarter are −0.48 USD. See more details about Tyra Biosciences, Inc. earnings.
Yes, you can track Tyra Biosciences, Inc. financials in yearly and quarterly reports right on TradingView.
TYRA stock has fallen by 4.62% compared to the previous week, the month change is a 9.62% fall, over the last year Tyra Biosciences, Inc. has showed a 0.48% increase.
TYRA net income for the last quarter is −22.83 M USD, while the quarter before that showed −21.15 M USD of net income which accounts for −7.93% change. Track more Tyra Biosciences, Inc. financial stats to get the full picture.
Today Tyra Biosciences, Inc. has the market capitalization of 630.74 M, it has increased by 1.91% over the last week.
No, TYRA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, TYRA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Tyra Biosciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 49.00 employees. See our rating of the largest employees — is Tyra Biosciences, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Tyra Biosciences, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Tyra Biosciences, Inc. stock shows the buy signal. See more of Tyra Biosciences, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Tyra Biosciences, Inc. future price: according to them, TYRA price has a max estimate of 28.00 USD and a min estimate of 22.00 USD. Read a more detailed Tyra Biosciences, Inc. forecast: see what analysts think of Tyra Biosciences, Inc. and suggest that you do with its stocks.